{
  "trial_id": "NCT03395756",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "midluteal phase of their cycle",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": ">3ng/ml serum progesterone level",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "healthy, non-pregnant, non-breastfeeding, reproductive age women with regular ovulatory cycles",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "BMI 18-30 kg/m2",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Regular menses for the last 3 months",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Cycle duration 24 to 35 days",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "English- or Spanish-speaking",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Methodology: Participants will be assigned to one of three groups based on leading follicle size",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Participants will undergo screening, which will include a history, physical exam, assessment of vital signs, and blood draw for assessment of ovulation via mid-luteal progesterone levels",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "If her progesterone level confirms ovulatory status (> 3 ng/ml), she will be offered enrollment and assigned to one of three follicular phase groups based on her leading follicle size in the next cycle",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "To determine follicle size, participants will receive serial transvaginal ultrasound (TVUS) scans of their ovarian follicles starting on cycle day 8 of the next menstrual cycle",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "The proposed study will enroll 36 healthy, non-pregnant, non-breastfeeding, reproductive age women with regular ovulatory cycles",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Any contraindications to progesterone contraception per teh CDC Medical Eligibility Criteria (Category 3 or 4)",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "On medications that can alter, or be altered by, progesterone contraceptive steroid hormone",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Use of any hormonal contraceptive pill, patch, or vaginal ring in the month prior to recruitment",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Currently pregnant and/or breastfeeding",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "History of allergic reaction to depot medroxyprogesterone acetate (rash, urticaria, anaphylaxis)",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "The patient is a healthy woman with regular ovulatory cycles and no contraindications to progesterone contraception. She meets most of the inclusion criteria and does not meet any of the exclusion criteria.",
  "_meta": {
    "topic_id": "69",
    "trial_id": "NCT03395756",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}